Novo Nordisk A/S (NVO)
Novo Nordisk A/S is a global healthcare company based in Denmark, specializing in the research, development, and manufacturing of pharmaceutical products. The company is a leader in diabetes care and is also involved in areas such as hemophilia care, growth hormone therapy, and hormone replacement therapy. Additionally, Novo Nordisk produces the successful weight loss drug, Wegovy.
Company Info
Highlights
$289.83B
$3.53
18.53
0.98
$303.14B
$255.65B
$154.08B
$57.00 - $145.26
$89.63
0.79%
2.44
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Novo Nordisk A/S (NVO) returned -23.92% year-to-date (YTD) and -50.58% over the past 12 months. Over the past 10 years, NVO had an annualized return of 10.77%, just below the S&P 500 benchmark at 10.78%.
NVO
-23.92%
-2.50%
-38.78%
-50.58%
17.02%
10.77%
^GSPC (Benchmark)
0.19%
9.00%
-1.55%
12.31%
15.59%
10.78%
Monthly Returns
The table below presents the monthly returns of NVO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -1.83% | 7.34% | -22.16% | -4.31% | -3.07% | -23.92% | |||||||
| 2024 | 10.91% | 4.38% | 7.98% | -0.07% | 5.43% | 5.51% | -7.08% | 5.32% | -14.44% | -5.98% | -4.60% | -19.46% | -15.94% |
| 2023 | 2.54% | 1.59% | 13.78% | 5.00% | -3.97% | 0.85% | -0.45% | 15.77% | -2.01% | 6.19% | 5.46% | 1.58% | 54.84% |
| 2022 | -10.83% | 3.08% | 8.90% | 2.66% | -3.16% | 0.93% | 4.16% | -8.09% | -6.10% | 9.24% | 14.48% | 8.62% | 22.66% |
| 2021 | -0.36% | 2.37% | -4.03% | 9.69% | 6.69% | 6.17% | 10.54% | 8.55% | -3.96% | 14.71% | -3.00% | 4.84% | 63.52% |
| 2020 | 5.10% | -4.44% | 5.01% | 5.20% | 4.12% | -0.70% | -0.23% | 1.88% | 5.13% | -7.98% | 5.07% | 4.05% | 23.32% |
| 2019 | 2.06% | 4.10% | 8.51% | -6.31% | -3.69% | 8.14% | -6.11% | 9.71% | -0.79% | 6.81% | 1.68% | 3.08% | 28.70% |
| 2018 | 3.41% | -7.24% | -3.01% | -4.69% | 1.28% | -2.99% | 7.91% | -0.23% | -4.13% | -8.40% | 7.97% | -1.18% | -12.12% |
| 2017 | 0.86% | -2.32% | -1.04% | 12.84% | 9.54% | 1.23% | -1.14% | 13.47% | 1.11% | 3.41% | 3.98% | 3.67% | 54.23% |
| 2016 | -3.81% | -8.00% | 7.29% | 2.95% | 0.45% | -4.03% | 5.93% | -17.21% | -10.98% | -14.55% | -5.46% | 6.73% | -36.56% |
| 2015 | 5.29% | 7.16% | 13.56% | 5.39% | 0.37% | -3.05% | 7.67% | -6.26% | -1.86% | -1.95% | 3.37% | 5.66% | 39.39% |
| 2014 | 7.36% | 19.81% | -2.16% | -0.57% | -6.85% | 9.25% | -0.30% | -0.20% | 3.61% | -5.12% | 0.62% | -6.91% | 16.67% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NVO is 4, meaning it’s performing worse than 96% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Novo Nordisk A/S provided a 2.50% dividend yield over the last twelve months, with an annual payout of $1.61 per share. The company has been increasing its dividends for 7 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.61 | $1.44 | $1.04 | $0.81 | $0.75 | $0.65 | $0.62 | $0.57 | $0.57 | $0.71 | $0.38 | $0.42 |
Dividend yield | 2.50% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Monthly Dividends
The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $1.10 | $0.00 | $0.00 | $1.10 | |||||||
| 2024 | $0.00 | $0.00 | $0.93 | $0.00 | $0.00 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.00 | $0.00 | $1.44 |
| 2023 | $0.00 | $0.00 | $0.59 | $0.00 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.00 | $1.04 |
| 2022 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.00 | $0.00 | $0.29 | $0.00 | $0.00 | $0.00 | $0.00 | $0.81 |
| 2021 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.00 | $0.00 | $0.75 |
| 2020 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.00 | $0.00 | $0.26 | $0.00 | $0.00 | $0.00 | $0.00 | $0.65 |
| 2019 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.00 | $0.62 |
| 2018 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.00 | $0.00 | $0.23 | $0.00 | $0.00 | $0.00 | $0.00 | $0.57 |
| 2017 | $0.00 | $0.00 | $0.33 | $0.00 | $0.00 | $0.00 | $0.00 | $0.24 | $0.00 | $0.00 | $0.00 | $0.00 | $0.57 |
| 2016 | $0.00 | $0.00 | $0.48 | $0.00 | $0.00 | $0.00 | $0.00 | $0.22 | $0.00 | $0.00 | $0.00 | $0.00 | $0.71 |
| 2015 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.38 |
| 2014 | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.42 |
Dividend Yield & Payout
Dividend Yield
Novo Nordisk A/S has a dividend yield of 2.50%, which is quite average when compared to the overall market.
Payout Ratio
Novo Nordisk A/S has a payout ratio of 11.20%, which is below the market average. This means Novo Nordisk A/S returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Novo Nordisk A/S was 71.29%, occurring on Oct 19, 1987. Recovery took 835 trading sessions.
The current Novo Nordisk A/S drawdown is 55.28%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -71.29% | Sep 21, 1983 | 1031 | Oct 19, 1987 | 835 | Feb 6, 1991 | 1866 |
| -59.68% | Jun 26, 2024 | 204 | Apr 17, 2025 | — | — | — |
| -51.28% | Aug 7, 2001 | 247 | Aug 5, 2002 | 381 | Feb 9, 2004 | 628 |
| -46.15% | Aug 4, 2015 | 332 | Nov 23, 2016 | 289 | Jan 19, 2018 | 621 |
| -42.91% | May 5, 1998 | 222 | Mar 22, 1999 | 300 | May 26, 2000 | 522 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Novo Nordisk A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Novo Nordisk A/S, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 609.8% positive surprise.
Valuation
The Valuation section provides an overview of how Novo Nordisk A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for NVO, comparing it with other companies in the Biotechnology industry. Currently, NVO has a P/E ratio of 18.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for NVO compared to other companies in the Biotechnology industry. NVO currently has a PEG ratio of 1.0. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NVO relative to other companies in the Biotechnology industry. Currently, NVO has a P/S ratio of 1.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NVO in comparison with other companies in the Biotechnology industry. Currently, NVO has a P/B value of 13.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |